ライフサイエンスコーパス: cryoglobulinemia

1 with IgG3-IgG2a complexes in BALB/c (type II cryoglobulinemia).

2 bacterial endocarditis causing his type III cryoglobulinemia.

3 portant etiologically in the pathogenesis of cryoglobulinemia.

4 ion for therapeutically challenging cases of cryoglobulinemia.

5 herapeutic options remain limited for type I cryoglobulinemia.

6 eutical formulations and in vivo in cases of cryoglobulinemia.

7 olutions of antibodies and the mechanisms of cryoglobulinemia.

8 at greater risk of developing CKD, MPGN, and cryoglobulinemia.

9 th the renal injury and systemic features of cryoglobulinemia.

10 Risks were also increased for cryoglobulinemia.

11 patitis occurring in the setting of systemic cryoglobulinemia.

12 utic strategy for preventing renal injury in cryoglobulinemia.

13 disease, IgM-mediated neuropathies and mixed cryoglobulinemia.

14 ignificant association between cirrhosis and cryoglobulinemia.

15 show clinical or physical signs of syndromic cryoglobulinemia.

16 tients had PCT, vitiligo, lichen planus, and cryoglobulinemia.

17 ry that resembles important aspects of human cryoglobulinemia.

18 itis syndrome, Sjogren's syndrome, and mixed cryoglobulinemia.

19 s (HCV) infection is associated with type II cryoglobulinemia.

20 , for an overall prevalence of 3.0% in mixed cryoglobulinemia.

21 tion does not appear to have a role in mixed cryoglobulinemia.

22 patient was also found to have type II mixed cryoglobulinemia.

23 omerulonephritis, with or without associated cryoglobulinemia.

24 pheresis for the presumed essential type III cryoglobulinemia.

25 argest cohort of patients with type II mixed cryoglobulinemia.1 Steroids and rituximab appear to be t

26 HCV is also the major cause of mixed cryoglobulinemia, a B-lymphocyte proliferative disorder.

27 al lymphopoietin transgenic mice, a model of cryoglobulinemia and associated membranoproliferative gl

28 yte proliferative disorders, including mixed cryoglobulinemia and B-cell lymphoma.

29 A woman in her 50s with cryoglobulinemia and bilateral lower extremity ulcers of

30 in (TSLP) transgenic mice that produce mixed cryoglobulinemia and develop hepatitis.

31 fficulty of identifying infectious causes of cryoglobulinemia and emphasizes that an initial, highly

32 tic manifestations of hepatitis C, including cryoglobulinemia and glomerulonephritis.

33 coinfection with HGV in patients with mixed cryoglobulinemia and HCV infection in the United States.

34 ases, and type II/III, which is called mixed cryoglobulinemia and is seen in hepatitis C virus infect

35 Patients with HCV may develop mixed cryoglobulinemia and its sequelae, ranging from cutaneou

36 s well as extrahepatic complications such as cryoglobulinemia and lymphoma.

37 inib may be a novel therapeutic approach for cryoglobulinemia and MPGN in humans.

38 tion, particularly its relationship to mixed cryoglobulinemia and related clinical syndromes.

39 ransgenic (TSLPtg) mice, which develop mixed cryoglobulinemia and severe cryoglobulinemia-associated

40 ween the prevalence in patients with type II cryoglobulinemia and the other populations studied.

41 observed infrequently in patients with mixed cryoglobulinemia and were caused by nonspecific binding

42 and function: autoantibody production, mixed cryoglobulinemia, and B cell lymphomas.

43 14 patients with HCV infection and type III cryoglobulinemia, and in 5 (13.5%) of 37 patients with H

44 found in patients with HCV infection without cryoglobulinemia, and in that population, the maximum an

45 Although hypocomplementemia, cryoglobulinemia, and more prominent hypertension and mi

46 bulinemia, none of 29 patients with type III cryoglobulinemia, and none of 6 patients with EMC were p

47 kin lymphoma, Waldenstrom macroglobulinemia, cryoglobulinemia, and thyroiditis were all <.0038, the B

48 patients with HCV infection with and without cryoglobulinemia, anti-CCP was not observed in patients

49 cal benefit in systemic lupus erythematosus, cryoglobulinemia, antineutrophil cytoplasmic antibodies+

50 iate logistic regression analysis identified cryoglobulinemia as an independent prognostic factor of

51 s with type II and 29 patients with type III cryoglobulinemia associated with HCV infection, 6 patien

52 ch develop mixed cryoglobulinemia and severe cryoglobulinemia-associated membranoproliferative glomer

53 us-prone MRL-Fas(lpr) mice can induce GN and cryoglobulinemia, but the features that confer nephritog

54 patic manifestations of HCV infection: mixed cryoglobulinemia, chronic kidney or end-stage renal dise

55 scosity, peripheral neuropathy, amyloidosis, cryoglobulinemia, cold-agglutinin disease, or evidence o

56 scosity, peripheral neuropathy, amyloidosis, cryoglobulinemia, cold-agglutinin disease, or transforme

57 sisted of the IgG3 cryoglobulin only (type I cryoglobulinemia) compared with IgG3-IgG2a complexes in

58 We propose that HCV-associated cryoglobulinemia could become clinically significant onl

59 systemic vasculitis associated with type II cryoglobulinemia (cryoglobulinemic vasculitis), a prolif

60 of clinical syndromes, including "essential" cryoglobulinemia (elicited by the hepatitis viruses) and

61 V infection, 6 patients with essential mixed cryoglobulinemia (EMC; all with type II), 50 hospital co

62 patic manifestations include sicca syndrome, cryoglobulinemia, glomerulonephritis, and porphyria cuta

63 role for hepatitis G virus (HGV) in type II cryoglobulinemia has not been defined, although prevalen

64 as high as 43% of HGV infections in type II cryoglobulinemia have also been reported.

65 sk of MPGN (HR, 2.23; 95% CI, 1.84-2.71) and cryoglobulinemia (HR, 16.91; 95% CI, 12.00-23.81) respec

66 ulins, and HCV, but not HGV, correlated with cryoglobulinemia in a longitudinal study.

67 oproliferative glomerulonephritis (MPGN) and cryoglobulinemia in chronic HCV patients.

68 Essential mixed cryoglobulinemia in humans is strongly associated with c

69 We characterized the role of cryoglobulinemia in the development of liver disease in

70 obulinemia, sera from 29 patients with mixed cryoglobulinemia (including 13 with rheumatic symptoms a

71 Cryoglobulinemia is a distinct entity characterized by t

72 Cryoglobulinemia is categorized into two main subgroups:

73 Essential mixed cryoglobulinemia is frequently associated with chronic h

74 itive anti-nuclear autoantibodies, and mixed cryoglobulinemia is increasingly reported in different p

75 f HCV with the extrahepatic complications of cryoglobulinemia is widely recognized, the relationship

76 lymphoproliferative disorders such as mixed cryoglobulinemia (MC) and B-cell non-Hodgkin lymphoma (B

77 e B-cell lymphoproliferative disorders mixed cryoglobulinemia (MC) and non-Hodgkin lymphoma.

78 Hepatitis C virus (HCV) causes mixed cryoglobulinemia (MC) by driving clonal expansion of IgM

79 Mixed cryoglobulinemia (MC) is the most common extrahepatic ma

80 Hepatitis C virus (HCV)-associated mixed cryoglobulinemia (MC) vasculitis commonly regresses upon

81 titis C virus (HCV) frequently develop mixed cryoglobulinemia (MC), a monoclonal expansion of immunog

82 in hepatitis C virus (HCV)-associated mixed cryoglobulinemia (MC), especially concerning the long-te

83 infection and PCT, lichen planus, vitiligo, cryoglobulinemia, membranoproliferative GN, and NHL.

84 Waldenstrom macroglobulinemia (n = 165), and cryoglobulinemia (n = 551) were increased with HCV infec

85 9%) of 34 patients with HCV-infected type II cryoglobulinemia, none of 29 patients with type III cryo

86 drome (P = 0.05), hypertension (P < 0.0001), cryoglobulinemia (P = 0.05), and preexisting intraocular

87 Two (6.9%) of the cryoglobulinemia patients had borderline-positive findin

88 Of the cryoglobulinemia patients, 22 (76%) had positive results

89 sociated with resolution of complications of cryoglobulinemia, reduced levels of insulin resistance,

90 m 50 patients with HCV infection but without cryoglobulinemia, sera from 29 patients with mixed cryog

91 The treatment of cryoglobulinemia should target the underlying disorder;

92 irus (HCV) is the most common cause of mixed cryoglobulinemia syndrome (MCS).

93 The majority of patients had cryoglobulinemia that became negative after HEV clearanc

94 We report a case of recalcitrant type I cryoglobulinemia treated successfully with long-term pla

95 ransgenic animals developed polyclonal mixed cryoglobulinemia (type III) and a systemic inflammatory

96 There was no apparent difference between cryoglobulinemia types I and II regarding the role of co

97 hepatitis C virus (HCV) infection, and overt cryoglobulinemia vasculitis (CryoVas) develops in approx

98 herapeutic management of noninfectious mixed cryoglobulinemia vasculitis (CryoVas) in the era of hepa

99 e in patients with hepatitis C virus-induced cryoglobulinemia vasculitis (HCV-CV).

100 Cryoglobulinemia was induced by i.p. injection of 6-19 h

101 hospital, a diagnosis of essential type III cryoglobulinemia was made.

102 irty-six HCV patients with and without mixed cryoglobulinemia were compared with 18 healthy control v

103 Hypocomplementemia and cryoglobulinemia were present in 46 and 33% of patients,

104 le mouse model of renal involvement in mixed cryoglobulinemia, which enables detailed studies of a me

105 ia is widely recognized, the relationship of cryoglobulinemia with liver disease is unclear.

106 on for end-stage chronic hepatitis C in whom cryoglobulinemia with vasculitis developed after transpl